Search

Displaying results 4191 - 4200 of 10000 in total
  1. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

  2. Drug

    Tolu balsam

    go.drugbank.com/drugs/DB11223
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Trandolaprilat

    go.drugbank.com/drugs/DB14209
    Experimental

    The active metabolite of the prodrug Trandolapril.

    Categories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    Thenoyltrifluoroacetone

    go.drugbank.com/drugs/DB04795
    Experimental

    Thenoyltrifluoroacetone is a chelating agent and inhibitor of cellular respiration.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  6. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  7. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate].

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. … It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive

  10. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE